ArticleClinics (Sao Paulo, Brazil)2026
An 8-gene diabetes-related signature predicts survival and immunotherapy response in breast cancer.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a signature of Diabetes-Related Genes (DRGs) using data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to predict the prognosis of Breast Cancer (BRCA) patients and identify potential therapeutic targets.
methodsA list of DRGs was sourced from the GeneCard database. Analyses of differential expression and consensus clustering were conducted to identify DRGs, and Cox regression and Least Absolute Shrinkage and Selection Operator (Lasso) regression were used to construct prognostic risk signatures based on DRGs. High- and low-risk groups were classified using median risk scores, and nomogram plots were created to visualize prognostic signatures. The relationship between immune infiltration, chemotherapeutic agents, and risk scores was evaluated, along with the expression of DRGs in individual immune cells.
resultsA total of 1231 RNA-seq samples (cancer: 1118, paraneoplastic: 113), 1046 clinical data, and 965 DRGs were obtained from the databases. Differential expression and consensus clustering analyses identified 224 differentially expressed DRGs. Cox regression and Lasso regression analyses led to the establishment of a prognostic signature based on 8 DRGs. Kaplan-Meier curves demonstrated that patients in the low-risk group had a significantly better prognosis compared to those in the high-risk group (p < 0.001). The calibrated curves of the nomogram at 1-, 2-, 3-, and 5-years all aligned with the diagonal, indicating that our nomogram has high predictive performance. Immune infiltration analysis showed significant correlations between our constructed signature and the relative abundance of immune cells (p < 0.05). Single-cell data analysis revealed that DRGs were predominantly expressed in CD4+ conventional T-cells and regulatory T-cells.
conclusionThis study has successfully developed a prognostic signature for DRGs, which can be utilized as an efficient tool for risk stratification and prognostic prediction in BRCA patients. Additionally, this research offers a novel basis for investigating potential immunotherapy targets for BRCA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.